These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 8098254)

  • 21. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats].
    Wang S; Qi XJ; Han D
    Zhongguo Zhen Jiu; 2009 May; 29(5):391-4. PubMed ID: 19489498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia.
    Ichinose H; Ohye T; Fujita K; Pantucek F; Lange K; Riederer P; Nagatsu T
    J Neural Transm Park Dis Dement Sect; 1994; 8(1-2):149-58. PubMed ID: 7893377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic lesions differentially decrease tyrosine hydroxylase messenger RNA in dopaminergic neurons of the substantia nigra.
    Pasinetti GM; Lerner SP; Johnson SA; Morgan DG; Telford NA; Finch CE
    Brain Res Mol Brain Res; 1989 May; 5(3):203-9. PubMed ID: 2566883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nurr1 in Parkinson's disease and related disorders.
    Chu Y; Le W; Kompoliti K; Jankovic J; Mufson EJ; Kordower JH
    J Comp Neurol; 2006 Jan; 494(3):495-514. PubMed ID: 16320253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.
    Gründemann J; Schlaudraff F; Haeckel O; Liss B
    Nucleic Acids Res; 2008 Apr; 36(7):e38. PubMed ID: 18332041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of aging on the dopaminergic neurons in the substantia nigra pars compacta of rats.
    Gao J; Miao H; Xiao CH; Sun Y; Du X; Yuan HH; Yu HL; Gao DS
    Curr Aging Sci; 2011 Feb; 4(1):19-24. PubMed ID: 21204780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study.
    Benisty S; Boissiere F; Faucheux B; Agid Y; Hirsch EC
    Neuroscience; 1998 Oct; 86(3):813-26. PubMed ID: 9692719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.
    Wang YQ; Bian GL; Bai Y; Cao R; Chen LW
    Neurochem Int; 2008 Sep; 53(3-4):56-62. PubMed ID: 18639597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperprolactinemia increases and hypoprolactinemia decreases tyrosine hydroxylase messenger ribonucleic acid levels in the arcuate nuclei, but not the substantia nigra or zona incerta.
    Arbogast LA; Voogt JL
    Endocrinology; 1991 Feb; 128(2):997-1005. PubMed ID: 1703487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.
    Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC
    Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of non-phosphorylated neurofilament immunoreactivity, with preservation of tyrosine hydroxylase, in surviving substantia nigra neurons in Parkinson's disease.
    Gai WP; Vickers JC; Blumbergs PC; Blessing WW
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1039-46. PubMed ID: 7916375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
    Iwata SI; Nomoto M; Fukuda T
    Synapse; 2001 Jan; 39(1):16-22. PubMed ID: 11071705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
    Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
    J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of age-related changes in nigral dopaminergic neurons of Asian Indians: relevance to lower incidence of Parkinson's disease.
    Alladi PA; Mahadevan A; Yasha TC; Raju TR; Shankar SK; Muthane U
    Neuroscience; 2009 Mar; 159(1):236-45. PubMed ID: 19135503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.
    Uhl GR; Walther D; Mash D; Faucheux B; Javoy-Agid F
    Ann Neurol; 1994 Apr; 35(4):494-8. PubMed ID: 8154880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Bukhatwa S; Zeng BY; Rose S; Jenner P
    Brain Res; 2010 Apr; 1326():174-83. PubMed ID: 20176003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
    Hurley MJ; Mash DC; Jenner P
    Eur J Neurosci; 2003 Nov; 18(9):2668-72. PubMed ID: 14622169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
    González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
    Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson's Disease.
    Rangasamy SB; Dasarathi S; Pahan P; Jana M; Pahan K
    J Neuroimmune Pharmacol; 2019 Jun; 14(2):173-187. PubMed ID: 30187283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.